Cargando…

Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers

Broadly neutralizing antibodies (bnAbs) against HIV-1 protect from infection and reduce viral load upon therapeutic applications. However no vaccine was able so far to induce bnAbs demanding their expensive biotechnological production. For clinical applications, nanobodies (VHH) derived from heavy c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Kathrin, Kalusche, Sarah, Torres, Jonathan L., Stanfield, Robyn L., Danquah, Welbeck, Khazanehdari, Kamal, von Briesen, Hagen, Geertsma, Eric R., Wilson, Ian A., Wernery, Ulrich, Koch-Nolte, Friedrich, Ward, Andrew B., Dietrich, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566552/ https://www.ncbi.nlm.nih.gov/pubmed/28827559 http://dx.doi.org/10.1038/s41598-017-08273-7

Ejemplares similares

Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability
por: Kong, Leopold, et al.
Publicado: (2016)

Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?
por: Kalusche, Sarah, et al.
Publicado: (2020)

Functional Characterization of Two scFv-Fc Antibodies from an HIV Controller Selected on Soluble HIV-1 Env Complexes: A Neutralizing V3- and a Trimer-Specific gp41 Antibody
por: Trott, Maria, et al.
Publicado: (2014)

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses
por: Curran, Rhonda M., et al.
Publicado: (2009)

Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer
por: He, Linling, et al.
Publicado: (2017)

Characterization and Immunogenicity of HIV Envelope gp140 Zera(®) Tagged Antigens
por: Ximba, Phindile, et al.
Publicado: (2020)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Antigenicity of soluble HIV gp140 trimers reveals differences in solution conformation for differing HIV strains
por: Gearhart, TL, et al.
Publicado: (2012)

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL
por: Isik, Gözde, et al.
Publicado: (2014)

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques
por: Jones, Andrew T., et al.
Publicado: (2018)

Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
por: Donnelly, Louise, et al.
Publicado: (2011)

Inverse dose-response to gp140 YU2 foldon trimer formulated with aluminum phosphate and ISCOMATRIX® adjuvants
por: Wilson, A, et al.
Publicado: (2012)

One-step sequence and structure-guided optimization of HIV-1 envelope gp140
por: Malladi, Sameer Kumar, et al.
Publicado: (2020)

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen()
por: Mann, J.F.S., et al.
Publicado: (2012)

Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model
por: Nkolola, JP, et al.
Publicado: (2012)

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
por: Visciano, Maria Luisa, et al.
Publicado: (2013)

A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
por: Sanders, Rogier W., et al.
Publicado: (2013)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses
por: Bowder, Dane, et al.
Publicado: (2018)

Antigenic and immunosuppressive properties of a trimeric recombinant transmembrane envelope protein gp41 of HIV-1
por: Mühle, Michael, et al.
Publicado: (2017)

Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles
por: Kumar, Sonu, et al.
Publicado: (2021)

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers
por: Morris, Charles D., et al.
Publicado: (2017)

Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens
por: Margolin, Emmanuel, et al.
Publicado: (2019)

Nanobodies: new avenue to treat kidney disease
por: Wanner, Nicola, et al.
Publicado: (2021)

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo
por: Medina-Ramírez, Max, et al.
Publicado: (2017)

A Twin-Cysteine Motif in the V2 Region of gp120 Is Associated with SIV Envelope Trimer Stabilization
por: Bohl, Christopher, et al.
Publicado: (2013)

Nanobodies as modulators of inflammation: potential applications for acute brain injury
por: Rissiek, Björn, et al.
Publicado: (2014)

Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
por: Vyas, GN
Publicado: (2012)

P19-23. Putative prefusion mechanism of HIV-1 Env revealed by ligand-induced quaternary alterations in o-gp140 trimers
por: Moscoso, CG, et al.
Publicado: (2009)

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
por: Menzel, Stephan, et al.
Publicado: (2018)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
por: Donnelly, L, et al.
Publicado: (2009)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens
por: Whitaker, Neal, et al.
Publicado: (2019)

Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability
por: Dubrovskaya, Viktoriya, et al.
Publicado: (2019)

P05-07. Evaluation of peripheral and bone marrow B cell responses in rhesus macaques after immunization with soluble HIV-1 gp140 trimers
por: Sundling, C, et al.
Publicado: (2009)

Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel
por: Schäfer, Waldemar, et al.
Publicado: (2022)

Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy
por: Jank, Larissa, et al.
Publicado: (2019)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u8chdsta99qkf21idgvj3a2uar